Device Trial Radar · NCT02592499
Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
74
Actual
Start
Jun 2016
Primary completion
Oct 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Vastra Gotaland RegionGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Karolinska University Hospital; University Hospital, Linkoeping; Skane University Hospital; Uppsala University Hospital; University Hospital, Umeå; Region Örebro County
- First posted
- Oct 30, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a prospective, randomized, non-blinded, national, multi-center study. The study will consist of the assignment of eligible patients to treatment with either a HeartMate III (HM III) left ventricular assist device system or to pharmacological treatment (optimal medical management, OMM) according to current guidelines. Eighty (80) patients will be enrolled in this study and randomized in a 1:1 fashion between the HM III and OMM, based on a modified power calculation.
Conditions
- End-stage Heart Failure
Interventions
HM IIIDevice
OMM, optimal medical managementOther
Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival at two years of follow-upTime frame: 2 years,
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Sahlgrenska Univesitetssjukhustet, Transplantationscentrum
Gothenburg, Sweden
Linköping Univ Hospital
Linköping, Sweden
Skåne University Hospital
Lund, Sweden
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.